Bio Historical Balance Sheet

BIO Stock

USD 338.48 0.75 0.22%

Trend analysis of Bio Rad Laboratories balance sheet accounts such as Short Long Term Debt Total of 1.5 B, Other Current Liabilities of 317.1 M or Total Current Liabilities of 338.4 M provides information on Bio Rad's total assets, liabilities, and equity, which is the actual value of Bio Rad Laboratories to its prevalent stockholders. By breaking down trends over time using Bio Rad balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Bio Rad Laboratories latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bio Rad Laboratories is a good buy for the upcoming year.

Bio Rad Inventory

819.54 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

About Bio Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Bio Rad Laboratories at a specified time, usually calculated after every quarter, six months, or one year. Bio Rad Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Bio Rad and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Bio currently owns. An asset can also be divided into two categories, current and non-current.

Bio Rad Balance Sheet Chart

At this time, Bio Rad's Retained Earnings are very stable compared to the past year. As of the 28th of November 2024, Non Current Assets Total is likely to grow to about 9.7 B, while Total Current Liabilities is likely to drop about 338.4 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Cash And Short Term Investments

Add Fundamental

Total Assets

Total assets refers to the total amount of Bio Rad assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Bio Rad Laboratories books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Bio Rad balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bio Rad Laboratories are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Bio Rad Laboratories balance sheet. This account contains Bio Rad investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Bio Rad Laboratories fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most accounts from Bio Rad's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Bio Rad Laboratories current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	11.0M	1.2B	1.4B	1.5B
Total Assets	17.8B	13.5B	12.3B	12.9B

Short Long Term Debt Total Total Assets

Bio Rad balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Accounts Payable	Intangible Assets	Common Stock Total Equity	Common Stock
Total Assets		0.27	0.66	0.51	1.0	0.85	0.14	1.0	0.3	0.99	-0.75	0.71	0.4	0.46	0.97	0.71	0.03	-0.19	0.98	0.93	0.69	0.19	-0.12	0.42	-0.37	-0.37
Short Long Term Debt Total	0.27		0.28	-0.03	0.22	0.43	0.95	0.27	-0.08	0.18	0.35	0.81	0.27	0.22	0.47	0.63	0.28	-0.7	0.45	0.52	0.76	-0.03	-0.1	0.51	-0.33	-0.33
Other Current Liab	0.66	0.28		0.42	0.64	0.6	0.12	0.63	0.4	0.64	-0.46	0.51	0.56	0.53	0.68	0.58	0.46	-0.12	0.69	0.64	0.59	-0.13	-0.33	0.78	-0.59	-0.59
Total Current Liabilities	0.51	-0.03	0.42		0.5	0.72	-0.29	0.46	0.85	0.48	-0.56	0.43	0.73	0.78	0.4	0.53	0.38	0.48	0.5	0.34	0.5	0.65	0.49	0.39	-0.7	-0.7
Total Stockholder Equity	1.0	0.22	0.64	0.5		0.83	0.08	1.0	0.3	1.0	-0.78	0.67	0.38	0.44	0.96	0.68	0.0	-0.16	0.97	0.92	0.65	0.19	-0.12	0.39	-0.35	-0.35
Property Plant And Equipment Net	0.85	0.43	0.6	0.72	0.83		0.2	0.82	0.55	0.8	-0.5	0.84	0.65	0.78	0.83	0.92	0.29	-0.06	0.88	0.85	0.89	0.36	0.27	0.48	-0.72	-0.72
Net Debt	0.14	0.95	0.12	-0.29	0.08	0.2		0.15	-0.38	0.06	0.46	0.64	0.05	-0.04	0.35	0.44	0.17	-0.81	0.3	0.41	0.57	-0.16	-0.24	0.38	-0.07	-0.07
Retained Earnings	1.0	0.27	0.63	0.46	1.0	0.82	0.15		0.25	0.99	-0.74	0.69	0.34	0.4	0.97	0.67	-0.01	-0.23	0.97	0.93	0.67	0.19	-0.17	0.39	-0.31	-0.31
Cash	0.3	-0.08	0.4	0.85	0.3	0.55	-0.38	0.25		0.27	-0.41	0.32	0.71	0.76	0.21	0.42	0.35	0.54	0.31	0.18	0.39	0.42	0.47	0.37	-0.73	-0.73
Non Current Assets Total	0.99	0.18	0.64	0.48	1.0	0.8	0.06	0.99	0.27		-0.79	0.63	0.33	0.39	0.95	0.63	-0.04	-0.16	0.95	0.9	0.61	0.18	-0.16	0.36	-0.3	-0.3
Non Currrent Assets Other	-0.75	0.35	-0.46	-0.56	-0.78	-0.5	0.46	-0.74	-0.41	-0.79		-0.2	-0.3	-0.33	-0.61	-0.24	0.07	-0.39	-0.64	-0.48	-0.2	-0.2	0.04	-0.19	0.19	0.19
Cash And Short Term Investments	0.71	0.81	0.51	0.43	0.67	0.84	0.64	0.69	0.32	0.63	-0.2		0.55	0.57	0.81	0.89	0.26	-0.39	0.82	0.83	0.97	0.2	0.07	0.59	-0.58	-0.58
Net Receivables	0.4	0.27	0.56	0.73	0.38	0.65	0.05	0.34	0.71	0.33	-0.3	0.55		0.88	0.4	0.71	0.76	0.32	0.46	0.36	0.67	0.05	0.47	0.76	-0.88	-0.88
Common Stock Shares Outstanding	0.46	0.22	0.53	0.78	0.44	0.78	-0.04	0.4	0.76	0.39	-0.33	0.57	0.88		0.42	0.8	0.64	0.39	0.5	0.41	0.72	0.17	0.61	0.54	-0.97	-0.97
Non Current Liabilities Total	0.97	0.47	0.68	0.4	0.96	0.83	0.35	0.97	0.21	0.95	-0.61	0.81	0.4	0.42		0.76	0.07	-0.35	0.99	0.97	0.78	0.1	-0.2	0.51	-0.37	-0.37
Inventory	0.71	0.63	0.58	0.53	0.68	0.92	0.44	0.67	0.42	0.63	-0.24	0.89	0.71	0.8	0.76		0.46	-0.18	0.79	0.8	0.97	0.11	0.3	0.57	-0.78	-0.78
Other Current Assets	0.03	0.28	0.46	0.38	0.0	0.29	0.17	-0.01	0.35	-0.04	0.07	0.26	0.76	0.64	0.07	0.46		0.2	0.11	0.03	0.43	-0.14	0.27	0.63	-0.7	-0.7
Other Stockholder Equity	-0.19	-0.7	-0.12	0.48	-0.16	-0.06	-0.81	-0.23	0.54	-0.16	-0.39	-0.39	0.32	0.39	-0.35	-0.18	0.2		-0.28	-0.45	-0.28	0.17	0.59	-0.14	-0.29	-0.29
Total Liab	0.98	0.45	0.69	0.5	0.97	0.88	0.3	0.97	0.31	0.95	-0.64	0.82	0.46	0.5	0.99	0.79	0.11	-0.28		0.96	0.81	0.18	-0.12	0.52	-0.45	-0.45
Property Plant And Equipment Gross	0.93	0.52	0.64	0.34	0.92	0.85	0.41	0.93	0.18	0.9	-0.48	0.83	0.36	0.41	0.97	0.8	0.03	-0.45	0.96		0.81	0.09	-0.18	0.47	-0.37	-0.37
Total Current Assets	0.69	0.76	0.59	0.5	0.65	0.89	0.57	0.67	0.39	0.61	-0.2	0.97	0.67	0.72	0.78	0.97	0.43	-0.28	0.81	0.81		0.15	0.18	0.64	-0.73	-0.73
Short Term Debt	0.19	-0.03	-0.13	0.65	0.19	0.36	-0.16	0.19	0.42	0.18	-0.2	0.2	0.05	0.17	0.1	0.11	-0.14	0.17	0.18	0.09	0.15		0.29	-0.17	-0.09	-0.09
Accounts Payable	-0.12	-0.1	-0.33	0.49	-0.12	0.27	-0.24	-0.17	0.47	-0.16	0.04	0.07	0.47	0.61	-0.2	0.3	0.27	0.59	-0.12	-0.18	0.18	0.29		-0.13	-0.52	-0.52
Intangible Assets	0.42	0.51	0.78	0.39	0.39	0.48	0.38	0.39	0.37	0.36	-0.19	0.59	0.76	0.54	0.51	0.57	0.63	-0.14	0.52	0.47	0.64	-0.17	-0.13		-0.64	-0.64
Common Stock Total Equity	-0.37	-0.33	-0.59	-0.7	-0.35	-0.72	-0.07	-0.31	-0.73	-0.3	0.19	-0.58	-0.88	-0.97	-0.37	-0.78	-0.7	-0.29	-0.45	-0.37	-0.73	-0.09	-0.52	-0.64		1.0
Common Stock	-0.37	-0.33	-0.59	-0.7	-0.35	-0.72	-0.07	-0.31	-0.73	-0.3	0.19	-0.58	-0.88	-0.97	-0.37	-0.78	-0.7	-0.29	-0.45	-0.37	-0.73	-0.09	-0.52	-0.64	1.0

Click cells to compare fundamentals

Bio Rad Account Relationship Matchups

Bio Rad balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	8.0B	13.0B	17.8B	13.5B	12.3B	12.9B
Short Long Term Debt Total	439.8M	14.1M	11.0M	1.2B	1.4B	1.5B
Other Current Liab	158.5M	354.0M	404.9M	312.2M	302.0M	317.1M
Total Current Liabilities	905.5M	631.5M	680.9M	568.7M	522.8M	338.4M
Total Stockholder Equity	5.8B	9.9B	13.7B	9.6B	8.7B	9.2B
Property Plant And Equipment Net	701.2M	693.5M	695.8M	679.6M	723.7M	759.9M
Net Debt	(220.9M)	(648.1M)	(459.8M)	764.0M	1.0B	1.1B
Retained Earnings	5.5B	9.3B	13.5B	9.9B	9.3B	9.7B
Cash	660.7M	662.2M	470.8M	434.2M	404.0M	257.1M
Non Current Assets Total	5.8B	10.8B	15.8B	10.3B	9.3B	9.7B
Non Currrent Assets Other	(997.7B)	(2.1T)	(3.1T)	(1.8T)	96.4M	101.2M
Cash And Short Term Investments	1.1B	996.7M	875.5M	1.8B	1.6B	1.7B
Net Receivables	392.7M	419.4M	423.5M	494.6M	489.0M	272.4M
Common Stock Shares Outstanding	30.2M	30.2M	30.2M	29.8M	29.2M	29.1M
Liabilities And Stockholders Equity	8.0B	13.0B	17.8B	13.5B	12.3B	12.9B
Non Current Liabilities Total	1.3B	2.5B	3.4B	3.3B	3.0B	3.2B
Inventory	554.0M	622.3M	572.2M	719.3M	780.5M	819.5M
Other Current Assets	113.3M	97.5M	124.8M	153.3M	171.7M	92.3M
Other Stockholder Equity	371.6M	329.5M	335.4M	183.9M	(183.5M)	(174.3M)
Total Liab	2.3B	3.1B	4.1B	3.9B	3.6B	3.7B
Property Plant And Equipment Gross	701.2M	1.5B	1.5B	1.5B	1.8B	1.9B
Total Current Assets	2.2B	2.1B	2.0B	3.2B	3.0B	3.2B
Accumulated Other Comprehensive Income	(87.3M)	282.5M	(175.6M)	(466.8M)	(336.0M)	(319.2M)
Short Term Debt	426.2M	38.3M	36.9M	36.8M	40.4M	33.9M
Accounts Payable	287.1M	139.5M	141.9M	135.0M	144.6M	116.6M
Intangible Assets	145.5M	199.5M	253.9M	332.1M	320.5M	188.7M
Other Assets	40.3M	13K	82K	94.6M	85.1M	71.4M
Long Term Debt	13.6M	12.3M	10.5M	1.2B	1.2B	1.3B
Good Will	264.1M	291.9M	347.3M	406.5M	413.6M	339.1M
Treasury Stock	(38.4M)	(99.9M)	(106.3M)	(263.6M)	(237.2M)	(225.4M)
Property Plant Equipment	499.3M	491.4M	695.8M	498.6M	573.4M	371.9M
Current Deferred Revenue	33.7M	42.5M	50.9M	52.2M	35.8B	37.5B
Other Liab	1.2B	2.4B	3.4B	2.0B	2.3B	2.4B
Short Term Investments	459.5M	334.5M	404.7M	1.4B	1.2B	1.3B
Net Tangible Assets	5.8B	9.9B	13.1B	9.2B	10.6B	11.1B
Retained Earnings Total Equity	5.5B	9.3B	13.5B	9.9B	11.4B	12.0B
Capital Surpluse	410.0M	429.4M	441.7M	447.5M	514.6M	366.5M
Deferred Long Term Liab	997.8M	2.1B	3.1B	1.8B	2.0B	2.1B

Pair Trading with Bio Rad

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Rad position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Rad will appreciate offsetting losses from the drop in the long position's value.

Moving against Bio Stock

0.41	FDMT	4D Molecular Therapeutics	Pair Corr
0.4	ICU	LMF Acquisition Oppo	Pair Corr
0.36	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.33	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr

The ability to find closely correlated positions to Bio Rad could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Rad when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Rad - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Rad Laboratories to buy it.

The correlation of Bio Rad is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Rad moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Rad Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Bio Rad can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Bio Rad Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Rad's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Rad Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Rad Laboratories Stock:

How To Invest In Bio

Details

Is Bio Stock a good investment?

Details

What is Bio Rad's Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

5.412

Earnings Share

(28.09)

Revenue Per Share

90.815

Quarterly Revenue Growth

0.028

Return On Assets

0.0186

The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bio Historical Balance Sheet

Bio Rad Inventory

819.54 Million

About Bio Balance Sheet Analysis

Bio Rad Balance Sheet Chart

Total Assets

Total Current Liabilities

Cash And Short Term Investments

Bio Rad balance sheet Correlations

Bio Rad Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bio Rad balance sheet Accounts

Pair Trading with Bio Rad

Moving against Bio Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Retained Earnings	+ 1.0	Total Assets
Retained Earnings	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Total Stockholder Equity
Common Stock	+ 1.0	Common Stock Total Equity
Non Current Assets Total	+ 0.99	Total Assets

Common Stock	- 0.97	Common Stock Shares Outstanding
Common Stock Total Equity	- 0.97	Common Stock Shares Outstanding
Common Stock	- 0.88	Net Receivables
Common Stock Total Equity	- 0.88	Net Receivables
Other Stockholder Equity	- 0.81	Net Debt
Non Currrent Assets Other	- 0.79	Non Current Assets Total